Get the Stockscreener App
3.25
0.00%
0.00
After Hours:
3.34
0.09
+2.77%
Scisparc Ltd stock is traded at $3.25, with a volume of 21,427.
It is up +0.00% in the last 24 hours and down -46.19% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$3.25
Open:
$3.26
24h Volume:
21,427
Relative Volume:
0.00
Market Cap:
$1.74M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.4507
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
-19.15%
1M Performance:
-46.19%
6M Performance:
+1,087%
1Y Performance:
+1,212%
1-Day Range:
$3.20
$3.34
1-Week Range:
$3.20
$3.9413
52-Week Range:
$0.197
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
3.25 | 5.27M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Scisparc Ltd Stock (SPRC) Latest News
Live market analysis of SciSparc Ltd.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Is SciSparc Ltd. stock a top momentum playJuly 2025 Drop Watch & Advanced Technical Signal Analysis - newser.com
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Is SciSparc Ltd. stock entering bullish territoryTrade Risk Assessment & Precise Trade Entry Recommendations - newser.com
Heatmap analysis for SciSparc Ltd. and competitorsJuly 2025 Institutional & Weekly High Potential Stock Alerts - newser.com
Tools to monitor SciSparc Ltd. recovery probabilityPortfolio Profit Report & Technical Entry and Exit Alerts - newser.com
Scisparc Ltd (SPRC) Stock Price, News & Analyst Forecast - eToro
N2OFF (NASDAQ: NITO) closes MitoCareX merger; issues 40% of fully diluted shares - Stock Titan
Is SciSparc Ltd. stock in correction or buying zoneWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
SciSparc’s SCI-110 Study: A Potential Game-Changer for Tourette Syndrome - TipRanks
SciSparc gets Nasdaq extension to regain compliance - MSN
SciSparc Ltd. stock retracement – recovery analysis2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
What dividend safety score for SciSparc Ltd. stockJuly 2025 Closing Moves & Fast Moving Stock Watchlists - fcp.pa.gov.br
Is SciSparc Ltd. stock attractive for passive investorsJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - Fundação Cultural do Pará
SciSparc’s Promising Clinical Study on SCI-210 for Autism Spectrum Disorder - TipRanks
SciSparc Completes Acquisition of Neurothera Labs Inc. - TipRanks
Form 6-K: SciSparc finalizes TSXV deal, pharma portfolio moved - Stock Titan
SciSparc Completes Sale of MitoCareX to N2OFF, Enhancing Cancer Drug Discovery - MSN
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):